QIAGEN N.V.’s (QGEN) long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees significant opportunities for NGS (next-generation sequencing) to deliver on the vision of precision medicine. To support internal growth, QIAGEN heavily invests in research and development for the menu expansion of its key platforms. Yet, adverse macroeconomic impacts and fierce rivalry pose risks for QIAGEN’s o ...

The market expects Qiagen (QGEN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 5, 2025, might help the stock move higher if these key numbers are b ...

QIAGEN’s (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, a challenging macro environment and an intense competitive market may dent its results of operations. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving Growth for QGEN StockQIAGEN offers one of the broadest portfolios of molecular technologies for healthcare. The range of assays for diseases and biomarkers speeds up and simpli ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Qiagen (QGEN) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This diagnostic products maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 5.66%.For the most recent quarter, Qiag ...

QIAGEN N.V. (QGEN) recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study for 100,000 newborns to screen over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions.The latest partnership aims to broaden the utilization of QIAGEN’s Genomics portfolio.Likely Trend of QGEN Stock Following the NewsFollowing the announcement, shares of the company remaine ...

QIAGEN’s (QGEN) business is expected to benefit from its expanded test menu of key platforms and strategic collaborations. Yet, the company faces a challenging macro environment. An intense competitive environment and exchange rate fluctuations may dent the results of operations. The stock carries a Zacks Rank #3 (Hold).Factors Driving QGEN StockQIAGEN’s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and othe ...

QIAGEN N.V.’s (QGEN) solid potential in the molecular diagnostics area is poised to help it grow in the coming quarters. The company continues to progress with its test menu expansion, building a solid foundation to achieve its long-term targets. Strategic collaborations with Eli Lilly are helping it develop and market its existing and potential products. Meanwhile, the adverse impact of macroeconomic challenges as well as intense competition remain a concern for QIAGEN’s operations.In the past year, this Z ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

QIAGEN N.V. (QGEN) has announced plans to move its QIAstat-Dx operations to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Slated to open in early 2026, the new site builds on the long-standing presence of the company in the Barcelona area and will cover the entire value chain for the QIAstat-Dx system.The site will include teams such as Research & Development (R&D), Manufacturing, Sales, Marketing, Quality Assurance and Regulatory Affairs. Additionally, ...

QIAGEN N.V. (QGEN) recently launched two new tools for designing and ordering custom solutions to support microbial analysis of bacterial, fungal and viral targets. These new tools should enable researchers to customize their assays and panels for use on the QIAcuity digital PCR (dPCR) system and any third-party next-generation sequencing (NGS) system. These customizable digital PCR assays will be available on QIAGEN’s GeneGlobe web portal. QGEN Stock’s Trend Following the NewsSubsequent to the news, QGEN's ...